This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Implantable Tibial Neuromodulation Pivotal Study (TITAN 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05226286
Recruitment Status : Active, not recruiting
First Posted : February 7, 2022
Last Update Posted : January 5, 2024
Sponsor:
Information provided by (Responsible Party):
MedtronicNeuro

Brief Summary:
The purpose of this prospective, multicenter study is to assess the safety and efficacy of tibial neuromodulation using the Medtronic Tibial Neuromodulation (TNM) system.

Condition or disease Intervention/treatment Phase
Overactive Bladder Device: Medtronic Implantable Tibial Neuromodulation (TNM) System Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 188 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Implantable Tibial Neuromodulation Pivotal Study
Actual Study Start Date : January 31, 2022
Actual Primary Completion Date : October 10, 2023
Estimated Study Completion Date : April 2025

Intervention Details:
  • Device: Medtronic Implantable Tibial Neuromodulation (TNM) System
    Stimulation of the tibial nerve using Medtronic's tibial neuromodulation device.


Primary Outcome Measures :
  1. Primary Outcome [ Time Frame: 6 months ]
    Proportion of TNM subjects experiencing a reduction of 50% or more in daily urinary urge incontinence (UUI) episodes (UUI responder rate) at 6 months after device implant.


Secondary Outcome Measures :
  1. Secondary Objective [ Time Frame: 6 months ]
    Change in UUI episodes at 6 months compared to baseline in subjects with UUI at baseline.

  2. Secondary Objective [ Time Frame: 6 months ]
    Change in daily UF episodes at 6 months compared to baseline in subjects with UF at baseline.

  3. Secondary Objective [ Time Frame: 6 months ]
    Change in urinary urgency assessed through the UPS at 6 months compared to baseline.

  4. Secondary Objective [ Time Frame: 6 months ]

    Change in Overactive Bladder Quality of Life Questionnaire (OAB-q) health related quality of life (HRQL) Total Score at 6 months compared to baseline.

    Details related to OAB-Q HRQL:

    OAB-q HRQL minimum value total score: 33 OAB-q HRQL maximum value total score:198

    The outcome is worse the higher the value of the total score.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects 18 years of age or older
  2. Qualifying voiding diary
  3. Have a diagnosis of UUI for at least 6 months
  4. Failed and/or are not a candidate for conservative therapies.
  5. Willing and able to accurately complete study diaries, questionnaires, attend visits, operate the system, and comply with the study protocol
  6. Willing and able to provide signed and dated informed consent

Exclusion Criteria:

  1. Have primary stress incontinence
  2. History of a prior implantable tibial neuromodulation system
  3. Anatomical defects, clinically significant edema or previous surgeries which precludes use of the device
  4. Previous pelvic floor surgery in the last 6 months
  5. Women who are pregnant or planning to become pregnant during the course of the study
  6. Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol requirements.
  7. Concurrent participation in another clinical study that may add additional safety risks and/or confound study results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05226286


Locations
Show Show 29 study locations
Sponsors and Collaborators
MedtronicNeuro
Investigators
Layout table for investigator information
Study Director: Beth Michaud Medtronic
Layout table for additonal information
Responsible Party: MedtronicNeuro
ClinicalTrials.gov Identifier: NCT05226286    
Other Study ID Numbers: MDT20061
First Posted: February 7, 2022    Key Record Dates
Last Update Posted: January 5, 2024
Last Verified: January 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Male Urogenital Diseases
Lower Urinary Tract Symptoms
Urological Manifestations